BioSkryb Genomics

BioSkryb Genomics products, like ResolveDNA? are powered by primary template-directed amplification (PTA), a more uniform whole genome amplification method versus other whole genome amplification methods (Gonzalez-Pena et al. PNAS 2021). Today, neuroscience researchers are using ResolveDNA in a variety of applications, including whole genome amplification from pooled nuclei to define mosaic genotypes. Learn how Klein et al. used ResolveDNA to identify a mosaic MTOR variant in purified neuronal DNA in a patient with focal cortical dysplasia using a novel depth electrode harvesting technique: https://lnkd.in/ghXfY3sd To learn more about how BioSkryb Genomics enables cutting edge neuroscience research, check out how our products and services have enabled neurology and neuroscience researchers: https://lnkd.in/gRW9JEkS #genomics #multiomics #singlecell #neurology

Tomorrow, please join Techtum Lab, our full-service partner in the Nordics, for a webinar featuring technology from BioSkryb Genomics and S2 Genomics. Register today! ? https://lnkd.in/gX5QiKrC

Hematologic oncology researchers are faced with unique challenges in their translational studies. Rare malignant clones and persister cells facilitate resistance and recurrence, but these cells can be missed by bulk sequencing. Similarly, hematologic malignancies are driven by various sizes of genomic alterations, and it can be difficult to catalog single nucleotide variants (SNV), copy number variation (CNV), and structural variants (SV) in one assay. Moreover, consequences of SNV, CNV, and SV changes are not always obvious and DNA-only approaches can fail to identify the gene expression changes resulting from mutations. How are researchers supposed to cope? Enter BioSkryb Genomics. ResolveDNA? enables single-cell whole genome sequencing, empowering researchers to sensitively and precisely detect whole genome CNV and SNVs at a single-cell resolution. ResolveOME? allows investigators to move beyond inference from gene expression and define the genetic mechanisms controlling gene expression at a single-cell level. Join BioSkryb at #ASH24 in Booth 3421 to learn how our products, including the BaseJumper? bioinformatics platform and ResolveServices, can provide end-to-end solutions for your next scientific breakthrough. Not attending ASH? Learn more about how our single-cell solutions can overcome the challenges in hematologic oncology research here: https://lnkd.in/gwqX6xmg #genomics #multiomics #singlecell #oncology #hemeonc

Please join Techtum Lab, our full-service partner in the Nordics, for a webinar featuring technology from BioSkryb Genomics and S2 Genomics. Register today! ?? https://lnkd.in/gX5QiKrC

Webinar tomorrow, November 19th! Join Ruben van Boxtel, Ph.D., of the Princess Máxima Center for Pediatric Oncology as he presents how his group applies single-cell whole genome sequencing to explore why children develop cancer. By combining phylogenetic and mutational signature analyses, the van Boxtel group has found that the genetic alterations driving pediatric leukemia were often acquired years before diagnosis. Register now: https://lnkd.in/gBuPJVTE ? #SingleCell #PediatricLeukemia #ClonalEvolution #Webinar

Uncover the frontiers of viral vectors and their impact on gene therapy development with our white paper, “Comprehensive, Single-Cell Multiomic Analysis Is Needed for Safer Cell and Gene Therapies Developed with Lentiviral and Adeno-Associated Virus Technologies”. Whether you're a dedicated researcher, an innovative clinician, or a forward-thinking industry professional, this resource empowers you to confidently assess the safety and efficacy of cell and gene therapy candidates at a single-cell resolution. Read the full white paper here: https://lnkd.in/gb6jAUCd #OffTarget #CellTherapy #GeneTherapy #SingleCell?

BioSkryb Genomics invites you to a webinar on November 19th with featured speaker, Ruben van Boxtel, Ph.D. of the Princess Máxima Center for Pediatric Oncology. Aging is the primary risk factor for cancer, but children also develop the disease. In fact, some cancers, such as leukemia, display a higher incidence in children compared to adolescents, despite their younger cells having less age-related damage. In this webinar, Dr. van Boxtel will present how his group uses single-cell whole genome sequencing to trace the origins of pediatric leukemia and understand the processes that cause it. Register here: https://lnkd.in/gBuPJVTE #SingleCell #PediatricLeukemia #ClonalEvolution #Webinar

This week, join us at the annual Society for Basic Urologic Research | SBUR meeting on November 14th-17th! The event will be held in Scottsdale, Arizona. Connect with us and discover how our ?? ResolveDNA? & ResolveOME? kits ?? powered by PTA, can advance your urologic research. Unlock multiple tiers of dynamic molecular insights—all from a single cell. We hope to see you there! #genomics #multiomics #singlecell #oncology

Publication highlight: Wyler et al. Environment International, 2024 ? Learn how Wyler et al. used ResolveDNA? and other cutting-edge techniques in deep nucleic acid sequencing to define pathogen dynamics and discover novel viruses and enzymes. ? https://lnkd.in/gH5n4Jwx ? #WhatQuestionsWillYouAsk

An amazing number of novel gene editing tools have been developed since the introduction of CRISPR over 10 years ago. Considering the rapid pace of this field, creating custom assays to measure off-target edits for every type of gene editor may soon become impractical. BioSkryb’s products and services offer unique solutions for characterizing gene edited cells. ResolveDNA offers nearly complete (>95%) coverage of single-cell genomes, making it a powerful tool for deeply characterizing both on- and off-target gene edits regardless of the type of gene editor used. Want to learn more? To talk to a CGT expert today: bioskryb.com/cgt-contact/ #CRISPR #GeneEditing #OffTargets